title: [Impact of eradication of Pseudomonas aeruginosa on survival in Mexican patients with cystic fibrosis].
abstract: BACKGROUND
  Patients with cystic fibrosis (CF) present lower airway infection with Pseudomonas aeruginosa. Treatment of initial infection is fundamental to reduce subsequent damage.
  
  
  METHODS
  We evaluated the efficacy of eradication treatment of P. aeruginosa in patients with CF from northeast Mexico using two protocols: inhaled colistin/oral ciprofloxacin and nebulized tobramycin 300 mg/oral ciprofloxacin. The intervention group included 17 patients with CF and recent infection with P. aeruginosa. The control group consisted of 23 chronically colonized patients of comparable age.
  
  
  RESULTS
  Patients received 27 courses of eradication treatment. P. aeruginosa was eradicated in 21/27 (77.77%). The infection free period was 16.9, 11.7 months (colistin) and 17 ± 9.7 months (tobramycin) with no statistically significant difference (P = 0.97).
  
  
  CONCLUSIONS
  Treated patients maintained normal lung function, better nutritional status, and a better chest X-ray score. In the control group 17/23 (73.9%) patients died with no deaths in the study group.
authors.forename: Adriana Ester
authors.initials: AE
authors.lastname: Bustamante
authors.forename: Roberto
authors.initials: R
authors.lastname: Mercado-Longoria
authors.forename: Rolando
authors.initials: R
authors.lastname: Tijerina-Menchaca
authors.forename: Marcela
authors.initials: M
authors.lastname: Mas-Treviño
authors.forename: Julián N
authors.initials: JN
authors.lastname: Torres-Rodríguez
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D003091:Colistin / Q000008:administration & dosage / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology / Q000401:mortality; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008800:Mexico; D009752:Nutritional Status; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification*; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D014031:Tobramycin; D003091:Colistin